Appointment is effective on September 1, 2015
Gordon Dunn will continue as Vice President, Finance Director, Europe
ATHLONE, Ireland -- Innocoll AG (NASDAQ:INNL) today announced that Jose (Pepe) Carmona, previously the Chief Financial Officer of a division of Alcon, a Novartiscompany, has been appointed Chief Financial Officer effective September 1, 2015. Gordon Dunn, Innocoll's current Chief Financial Officer, will continue with the company as Vice President, Finance Director, Europe. The executive changes were made to add further commercialization experience to the senior management team as the company prepares to transition to a fully-integrated specialty pharmaceutical company.
"As Innocoll continues to execute on the transition of the organization, it is essential that our leadership team has the skills and experience required to successfully lead a commercial-stage company," said Tony Zook, Chief Executive Officer of Innocoll. "Jose's extensive background with major pharmaceutical and personal care companies is the skill set that will help propel the company to its next stage in its development. We very much thank Gordon for his contributions as CFO and appreciate his continued commitment to the company by heading our European financial operations."
Mr. Carmona has over 19 years of experience applying his extensive management skills toward the financial operations of commercial-stage companies. Most recently he served as Chief Financial Officer of Alcon Europe, Middle East & Africa, a division of Novartis, and prior to that he held numerous financial management positions with increasing responsibility within Novartis. Before joining Novartis in 2003, Mr. Carmona held senior management positions for several divisions of Proctor and Gamble in Latin America. Mr. Carmona received his B.S. in Industrial and Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.
"I am very pleased to be joining Innocoll at such an exciting stage in its development," said Mr. Carmona. "The company could face a rapid transition from a clinical development-stage company to a company with multiple self-marketed products in the very near term. It will be a momentous time at Innocoll and I look forward to contributing to the company's continued success."
Mr. Dunn added, "I am extremely proud of what we accomplished at Innocoll during my tenure as the company's CFO. We raised the capital necessary to build a strong drug formulation platform and set the stage for commercialization. I look forward to working with Pepe who will apply his commercial-stage experience toward moving the company to the next level at exactly the right time in the company's development."
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The company's approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma. All of the company's products and product candidates are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany. CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.